<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56032">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376699</url>
  </required_header>
  <id_info>
    <org_study_id>SGNS40-001</org_study_id>
    <nct_id>NCT02376699</nct_id>
  </id_info>
  <brief_title>Safety Study of SEA-CD40 in Cancer Patients</brief_title>
  <official_title>A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety profile of SEA-CD40. The study will test increasing doses
      of SEA-CD40 given at least every 3 weeks to small groups of patients. The goal is to find
      the highest dose of SEA-CD40 that can be given to patients that does not cause unacceptable
      side effects. Different dose regimens may also be evaluated to see if more SEA-CD40 can be
      given within a treatment cycle while maintaining an acceptable safety profile. The
      pharmacokinetics, pharmacodynamic effects, biomarkers of response, and antitumor activity of
      SEA-CD40 will also be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in the following parts:

      Part A: Dose-regimen finding for solid tumors -- Dose-escalation, and possible dose-interval
      modification to lengthen the treatment cycle, to define the maximum tolerated dose (MTD)
      and/or the optimal biological dose (OBD) regimens in patients with solid tumors. The ability
      to increase the dose intensity (to give additional doses within a treatment cycle) may be
      evaluated.

      Part B: Solid tumor expansion cohorts -- Disease-specific solid tumor expansion cohorts may
      be enrolled where patients will be treated with doses at or below the MTD and/or OBD
      determined in Part A.

      Part C: Dose-regimen finding for lymphomas -- Dose-escalation, and possible dose-interval
      modification to lengthen the treatment cycle, to define the MTD and/or the OBD regimens in
      patients with lymphomas. The ability to increase the dose intensity (to give additional
      doses within a treatment cycle) may be evaluated.

      Part D: Lymphoma expansion cohorts -- Disease-specific lymphoma expansion cohorts may be
      enrolled where patients will be treated with doses at or below the MTD and/or OBD determined
      in Part C.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through up to approximately 6 weeks following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of chemistry and hematology laboratory abnormalities</measure>
    <time_frame>Through up to approximately 6 weeks following last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of SEA-CD40</measure>
    <time_frame>Through up to approximately 6 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies against SEA-CD40</measure>
    <time_frame>Through up to approximately 6 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean absolute and percent change from baseline over time of selected pharmacodynamic markers</measure>
    <time_frame>Through up to approximately 6 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Through up to approximately 6 weeks following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Through up to approximately 6 weeks following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Cancer</condition>
  <condition>Carcinoma</condition>
  <condition>Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Hematologic Malignancies</condition>
  <condition>Hodgkin Disease</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, Follicular</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Solid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymphomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 Monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEA-CD40</intervention_name>
    <description>Given intravenously on Day 1 every 3 weeks; or Days 1 and 8 every 3 weeks for 2 cycles, and then Day 1 every 3 weeks in subsequent cycles. Number of cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Lymphomas</arm_group_label>
    <arm_group_label>Solid Tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed advanced malignancy, either: (a) Metastatic or unresectable
             solid malignancy; or (b) Classical Hodgkin lymphoma (HL), or diffuse large B-cell
             lymphoma (DLBCL), or indolent lymphoma (including follicular lymphoma [FL])

          -  Relapsed, refractory, or progressive disease, specifically: (a) Solid tumors:
             Following at least 1 prior systemic therapy, and no further standard therapy is
             available for the patient's advanced solid tumor at the time of enrollment; or (b)
             Classical HL: Following at least 2 prior systemic therapies in patients who are not
             candidates for autologous stem cell transplant (SCT), or following failure of
             autologous SCT; or (c) DLBCL: Following at least 1 prior systemic therapy; patients
             must have also received intensive salvage therapy unless they refused or were deemed
             ineligible; or (d) Indolent lymphoma: Following at least 1 prior chemoimmunotherapy
             regimen that included an anti-CD20 monoclonal antibody and for which no other more
             appropriate treatment option exists

          -  Representative baseline tumor tissue sample is available

          -  Measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate baseline hematologic, renal, and hepatic function

          -  Recovery to Grade 1 of any clinically significant toxicity prior to initiation of
             study drug administration

        Exclusion Criteria:

          -  Prior chemotherapy, small molecule inhibitors, radiation, and/or other
             investigational anticancer agents (excluding investigational monoclonal antibodies)
             within 2 weeks

          -  Prior immune-checkpoint inhibitors within 4 weeks

          -  Prior monoclonal antibodies, antibody-drug conjugates, or radioimmunoconjugates
             within 4 weeks (or 2 weeks if patient experienced disease progression on the prior
             treatment)

          -  Prior T-cell or other cell-based therapies within 12 weeks (or 2 weeks if patient
             experienced disease progression on the prior treatment)

          -  Recent or ongoing serious infections within 2 weeks

          -  Active autoimmune or auto-inflammatory ocular disease within 6 months

          -  Known or suspected active organ-threatening autoimmune disease

          -  Prior or current central nervous system tumor or metastases

          -  Patients with lymphomas: prior allogeneic SCT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Manley, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Scottsdale Shea Medical Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gordon, RN</last_name>
      <phone>480-323-1350</phone>
      <email>Michael.Gordon@HonorHealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Brandy Carothers</last_name>
      <phone>480-323-1323</phone>
      <email>brandy.carothers@honorhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Hoffman</last_name>
      <phone>773-834-7617</phone>
      <email>lhoffman2@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Gajewski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>University of Michigan Cancer Answer Line</last_name>
      <phone>800-865-1125</phone>
    </contact>
    <investigator>
      <last_name>David Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Kranwinkel</last_name>
      <phone>201-996-5900</phone>
      <email>GRACE.KRANWINKEL@HACKENSACKMERIDIAN.ORG</email>
    </contact>
    <investigator>
      <last_name>Martin Gutierrez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Ghalib</last_name>
      <phone>718-405-8515</phone>
      <email>mhghalib@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Sanjay Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center / University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Garbarino</last_name>
      <phone>984-974-8662</phone>
      <email>jennifer_garbarino@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Juneko Grilley-Olson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Sutcliffe</last_name>
      <phone>503-215-5763</phone>
      <email>kimberly.sutcliffe@providence.org</email>
    </contact>
    <investigator>
      <last_name>Brendan Curti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Hawkins</last_name>
      <phone>713-745-6784</phone>
      <email>chawkins@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Yasuhiro Oki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SCCA Phase 1 Program</last_name>
      <phone>206-288-7551</phone>
      <email>Phase1@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Coveler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>February 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD40 Antigen</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Hodgkin Disease</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Indolent Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphoma, B-Cell</keyword>
  <keyword>Lymphoma, Large B-Cell, Diffuse</keyword>
  <keyword>Lymphoma, Non-Hodgkin</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasm Metastasis</keyword>
  <keyword>Solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
